BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

498 related articles for article (PubMed ID: 27412393)

  • 1. Chemotherapy for Endometrial Cancer in Adjuvant and Advanced Disease Settings.
    Bestvina CM; Fleming GF
    Oncologist; 2016 Oct; 21(10):1250-1259. PubMed ID: 27412393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.
    de Boer SM; Powell ME; Mileshkin L; Katsaros D; Bessette P; Haie-Meder C; Ottevanger PB; Ledermann JA; Khaw P; Colombo A; Fyles A; Baron MH; Jürgenliemk-Schulz IM; Kitchener HC; Nijman HW; Wilson G; Brooks S; Carinelli S; Provencher D; Hanzen C; Lutgens LCHW; Smit VTHBM; Singh N; Do V; D'Amico R; Nout RA; Feeney A; Verhoeven-Adema KW; Putter H; Creutzberg CL;
    Lancet Oncol; 2018 Mar; 19(3):295-309. PubMed ID: 29449189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant chemotherapy for advanced endometrial cancer.
    Galaal K; Al Moundhri M; Bryant A; Lopes AD; Lawrie TA
    Cochrane Database Syst Rev; 2014 May; 2014(5):CD010681. PubMed ID: 24832785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial.
    de Boer SM; Powell ME; Mileshkin L; Katsaros D; Bessette P; Haie-Meder C; Ottevanger PB; Ledermann JA; Khaw P; D'Amico R; Fyles A; Baron MH; Jürgenliemk-Schulz IM; Kitchener HC; Nijman HW; Wilson G; Brooks S; Gribaudo S; Provencher D; Hanzen C; Kruitwagen RF; Smit VTHBM; Singh N; Do V; Lissoni A; Nout RA; Feeney A; Verhoeven-Adema KW; Putter H; Creutzberg CL;
    Lancet Oncol; 2019 Sep; 20(9):1273-1285. PubMed ID: 31345626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postoperative external beam radiation therapy and concurrent cisplatin followed by carboplatin/paclitaxel for stage III (FIGO 2009) endometrial cancer.
    Milgrom SA; Kollmeier MA; Abu-Rustum NR; Tew WP; Sonoda Y; Barakat RR; Alektiar KM
    Gynecol Oncol; 2013 Sep; 130(3):436-40. PubMed ID: 23800696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant carboplatin and paclitaxel chemotherapy interposed with involved field radiation for advanced endometrial cancer.
    Lupe K; D'Souza DP; Kwon JS; Radwan JS; Harle IA; Hammond JA; Carey MS
    Gynecol Oncol; 2009 Jul; 114(1):94-8. PubMed ID: 19406459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of node-positive endometrial cancer: chemotherapy, radiation, immunotherapy, and targeted therapy.
    Tubridy EA; Taunk NK; Ko EM
    Curr Treat Options Oncol; 2024 Mar; 25(3):330-345. PubMed ID: 38270800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant combined-modality therapy for stage IIIC endometrioid and non-endometrioid endometrial cancer.
    Chapman BV; Swanick CW; Ning MS; Allen PK; Soliman PT; Westin SN; Pardeshi V; Broaddus RR; Lu KH; Jhingran A; Eifel PJ; Klopp AH
    Gynecol Oncol; 2019 Jul; 154(1):22-28. PubMed ID: 31109659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant docetaxel and carboplatin chemotherapy administered alone or with radiotherapy in a "sandwich" protocol in patients with advanced endometrial cancer: a single-institution experience.
    Lan C; Huang X; Cao X; Huang H; Feng Y; Huang Y; Liu J
    Expert Opin Pharmacother; 2013 Apr; 14(5):535-42. PubMed ID: 23480059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The importance of adjuvant chemotherapy and pelvic radiotherapy in high-risk early stage endometrial carcinoma.
    Jutzi L; Hoskins P; Lim P; Aquino-Parsons C; Tinker A; Kwon JS
    Gynecol Oncol; 2013 Dec; 131(3):581-5. PubMed ID: 24055614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant carboplatin and paclitaxel with "sandwich" method radiotherapy for stage III or IV endometrial cancer: long-term follow-up at a single-institution.
    Chinnadurai A; Breadner D; Baloush Z; Lohmann AE; Black M; D'Souza D; Welch S
    J Gynecol Oncol; 2024 Mar; 35(2):e16. PubMed ID: 37921600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer.
    Alvarez Secord A; Havrilesky LJ; Bae-Jump V; Chin J; Calingaert B; Bland A; Rutledge TL; Berchuck A; Clarke-Pearson DL; Gehrig PA
    Gynecol Oncol; 2007 Nov; 107(2):285-91. PubMed ID: 17688923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of adjuvant therapy in stage IIIC2 endometrial cancer.
    Bogani G; Cappuccio S; Casarin J; Narasimhulu DMM; Cilby WA; Glaser GE; Weaver AL; McGree ME; Keeney GL; Weroha J; Petersen IA; Mariani A
    Int J Gynecol Cancer; 2020 Aug; 30(8):1169-1176. PubMed ID: 32646864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant Carboplatin and Paclitaxel Chemotherapy Followed by Radiotherapy in High-Risk Endometrial Cancer: A Retrospective Analysis.
    Rodrigues da Cunha Colombo Bonadio R; Gondim Meira Velame Azevedo R; Harada G; Cabral Severino da Costa S; Costa Miranda V; de Freitas D; Abdo Filho E; Alves de Oliveira Ferreira P; Gabrielli F; Del Pilar Estevez Diz M
    J Glob Oncol; 2018 Sep; 4():1-8. PubMed ID: 30241227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose adjuvant vaginal cylinder brachytherapy for early-stage non-endometrioid endometrial cancer: recurrence risk and survival outcomes.
    Smart A; Buscariollo D; Alban G; Buzurovic I; Cheng T; Pretz J; Krechmer B; King M; Lee L
    Int J Gynecol Cancer; 2020 Dec; 30(12):1908-1914. PubMed ID: 32655012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors and adjuvant chemotherapy in the treatment of endometrial cancer.
    Stanojevic Z; Djordjevic B; Todorovska I; Lilic V; Zivadinovic R; Dunjic O
    J BUON; 2008; 13(1):23-30. PubMed ID: 18404782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Taxane Plus Platinum Regimens vs Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk of Progression: A Randomized Clinical Trial.
    Nomura H; Aoki D; Michimae H; Mizuno M; Nakai H; Arai M; Sasagawa M; Ushijima K; Sugiyama T; Saito M; Tokunaga H; Matoda M; Nakanishi T; Watanabe Y; Takahashi F; Saito T; Yaegashi N;
    JAMA Oncol; 2019 Jun; 5(6):833-840. PubMed ID: 30896757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001.
    Marth C; Tarnawski R; Tyulyandina A; Pignata S; Gilbert L; Kaen D; Rubio MJ; Frentzas S; Beiner M; Magallanes-Maciel M; Farrelly L; Choi CH; Berger R; Lee C; Vulsteke C; Hasegawa K; Braicu EI; Wu X; McKenzie J; Lee JJ; Makker V
    Int J Gynecol Cancer; 2022 Jan; 32(1):93-100. PubMed ID: 34799418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant chemotherapy in endometrial cancer.
    Gómez-Raposo C; Merino Salvador M; Aguayo Zamora C; Casado Saenz E
    Cancer Chemother Pharmacol; 2020 Mar; 85(3):477-486. PubMed ID: 31950214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant paclitaxel and carboplatin chemotherapy with involved field radiation in advanced endometrial cancer: a sequential approach.
    Lupe K; Kwon J; D'Souza D; Gawlik C; Stitt L; Whiston F; Nascu P; Wong E; Carey MS
    Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):110-6. PubMed ID: 17084542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.